Medical News

RSS

Fovea's initiation of Prednisporin Phase 2b clinical testing triggers milestone payment to CombinatoRx

CombinatoRx, Incorporated today announced that it has received a milestone payment from Fovea Pharmaceuticals, a division of Sanofi Aventis, relating to Fovea's initiation of Phase 2b clinical testing of PrednisporinTM (FOV1101) in subjects with persistent allergic conjunctivitis. Prednisporin™ is a CombinatoRx-derived combination drug candidate that was exclusively licensed to Fovea by CombinatoRx.

7 Jun 2010

Israel's export of life sciences industry increases 14% in first-quarter 2010

"The first 2010 quarter export of the life sciences industry summed up to ca. $1.7 billion, an increase of about 14 percent compared to the same period last year. This increase is derived from a 15.4 percent increase in the export of medications, which has summed up to ca. $1.3 Billion; medical and surgical instrumentation had an increase of 7.5 percent, summing up to about $306 Million," said Mr. Avi Hefetz, the Chief Executive Officer of the Israel Export and International Cooperation Institute.

7 Jun 2010

EDEMA4 study results of KALBITOR for treatment of acute attacks of HAE published

Dyax Corp. announced today the publication of results from its second Phase 3, placebo-controlled trial, known as EDEMA4, evaluating KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema. The results, published in the June 2010 issue of the Annals of Allergy, Asthma, and Immunology, indicate that KALBITOR is effective in ameliorating HAE attacks, resolving associated symptoms and preventing attack progression.

7 Jun 2010

Oncolytics reports updated results from U.K. Phase I/II combination REOLYSIN trial at ASCO 2010

Oncolytics Biotech Inc. announced today that a poster presentation covering updated results of its Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers was presented today at the ASCO 2010 Annual Meeting in Chicago, IL.

7 Jun 2010

Leonardo Biosystems receives $2.5M grant to accelerate commercialization of new technologies

Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.

7 Jun 2010

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Chronix Biomedical today reported new data further demonstrating that its serum DNA blood tests have the potential to accurately detect early stage breast cancer and prostate cancer. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on circulating DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

7 Jun 2010

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it presented positive efficacy and safety data for its doxorubicin targeted conjugate compound, AEZS-108, in ovarian cancer.

7 Jun 2010

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Cancer diagnostics company Biomoda, Inc. has been granted a Mexican patent for its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce red under ultraviolet light.

7 Jun 2010

MiMedx' HydroFix Vaso Shield receives FDA clearance for additional thicknesses and sizes

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has received notification by the FDA that the Company's proprietary device, HydroFix™ Vaso Shield, has received 510(k) clearance for additional thicknesses and sizes.

7 Jun 2010

ACG-South Florida recognizes Continucare as Emerging Growth Company of the Year

Continucare Corporation today announced that it was named the Emerging Growth Company of the Year by the South Florida Chapter of the Association for Corporate Growth. The award recognizes South Florida's outstanding companies that are building and leading dynamic, growing businesses.

7 Jun 2010

Allergan receives CEO Cancer Gold Standard accreditation

Allergan, Inc. has received CEO Cancer Gold Standard™ accreditation, recognizing the organization's commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

7 Jun 2010

Microscopic image sensor to speed up detection of tumors

To diagnose cancer reliably, doctors usually conduct a biopsy including tissue ana-lysis - which is a time-consuming process. A microscopic image sensor, fitted in an endoscope, is being developed for in vivo cancer diagnosis, to speed up the detection of tumors.

7 Jun 2010

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

VIVUS, Inc. today announced positive results from the phase 3 REVIVE-Diabetes (TA-302) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in men with type 1 and type 2 diabetes. The REVIVE-Diabetes study met all three primary endpoints across the two doses studied by demonstrating statistically significant improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the International Index of Erectile Function (IIEF) score.

7 Jun 2010

Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting

Geron Corporation today announced the presentation of data from the clinical trial of imetelstat (GRN163L), the company's telomerase inhibitor drug, in combination with paclitaxel and bevacizumab in patients with breast cancer at the 2010 American Society of Clinical Oncology annual meeting in Chicago.

7 Jun 2010

Celera applies CE mark to real-time PCR test for detection of variant in KIF6 gene

Celera Corporation today announced that it has signed a Declaration of Conformity and applied the CE mark to a real-time PCR (polymerase chain reaction) test for detection of a variant in the KIF6 gene, allowing the test to be marketed in the European Union and other geographic areas that recognize the CE Mark.

7 Jun 2010

Medivo announces acquisition of PWN

Medivo, a provider of virtual healthcare services for individuals and organizations, announced today the acquisition of Physicians Wellness Network LLC, a leading provider of compliance services for online wellness screening tests.

7 Jun 2010

Study provides new insight into how brain responds to light

Exposure to extraordinarily brief, millisecond flashes of bright light improves alertness at night, according to a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

7 Jun 2010

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.

7 Jun 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

SCCT names finalists of fourth annual Young Investigator Award

The Society of Cardiovascular Computed Tomography, the leading international professional society dedicated to research, education and clinical excellence in cardiovascular computed tomography, has named the finalists of the fourth annual Young Investigator Award. Sponsored by Toshiba America Medical Systems, Inc. through an unrestricted educational grant, the Young Investigator Award will be awarded to two residents or fellows in either radiology or cardiology for their patient care research in the categories of technical and clinical advancement of cardiovascular CT.

7 Jun 2010

Medical News

Fovea's initiation of Prednisporin Phase 2b clinical testing triggers milestone payment to CombinatoRx

Israel's export of life sciences industry increases 14% in first-quarter 2010

EDEMA4 study results of KALBITOR for treatment of acute attacks of HAE published

Oncolytics reports updated results from U.K. Phase I/II combination REOLYSIN trial at ASCO 2010

Leonardo Biosystems receives $2.5M grant to accelerate commercialization of new technologies

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Biomoda granted Mexican patent for proprietary porphyrin-based compound

MiMedx' HydroFix Vaso Shield receives FDA clearance for additional thicknesses and sizes

ACG-South Florida recognizes Continucare as Emerging Growth Company of the Year

Allergan receives CEO Cancer Gold Standard accreditation

Microscopic image sensor to speed up detection of tumors

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting

Celera applies CE mark to real-time PCR test for detection of variant in KIF6 gene

Medivo announces acquisition of PWN

Study provides new insight into how brain responds to light

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

SCCT names finalists of fourth annual Young Investigator Award

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News